Nitric oxide

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting

Retrieved on: 
水曜日, 4月 19, 2023
TNBC, AACR, UNO, Neoplasm, Triple-negative breast cancer, Survival, Nitric oxide, Cancer, American Association for Cancer Research, Biomarker, Patient, Immune system, Pharmaceutical industry

GARDEN CITY, N.Y. and HAMILTON, Bermuda, April 19, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced promising new in vivo and in vitro data that support the potential of the company’s novel UNO therapy to treat various types of solid tumors as a single agent and in combination with checkpoint inhibitors. These data were presented today at the American Association for Cancer Research (AACR) Annual Meeting 2023, which is being held in Orlando, Florida from April 14th to 19th via poster presentations for abstract numbers 6327 and 6363.

Key Points: 
  • These data were presented today at the American Association for Cancer Research (AACR) Annual Meeting 2023, which is being held in Orlando, Florida from April 14th to 19th via poster presentations for abstract numbers 6327 and 6363.
  • “Today’s impressive new data demonstrating that UNO is effective in treating the aggressive murine breast cancer model (4T1) along with evidence of mPD-L1 upregulation is suggestive of UNO’s ability to sensitize tumors to checkpoint therapy.
  • In addition, we are pleased that these new data show efficacious responses from single and repeat doses of UNO,” stated Dr. Selena Chaisson, Chief Executive Officer and Director.
  • “These data are exciting additions to the growing body of evidence supporting UNO as a potential therapeutic option for cancer patients.

30 Technology’s Clinically Validated Antimicrobial Nitric Oxide Platform Acquired by Convatec Group Plc for Several Applications

Retrieved on: 
水曜日, 4月 19, 2023
Infection, COPD, Social work, LSE, Research and development, Therapy, Powder, CTEC, Stifel, Respiratory disease, Nitric oxide, Health, Immunity, Research, Cystic fibrosis, National Institute of General Medical Sciences, IP, Fungus, Sale, CN v Secretary of State for Health and Social Care, Divestment, NO, Patent, Patient, Ophthalmology, Convatec, Bacteria, NHS, Burns, Rare, Scottish Enterprise, Virus, Dentistry, Pharmaceutical industry, Vaccine, Bronchiectasis

London, UK, 19 April 2023 – 30 Technology, the world leader in clinical nitric oxide generation technology for health care, today announced that it has completed the sale of its antimicrobial nitric oxide platform in certain applications to Convatec Group Plc (LSE: CTEC).

Key Points: 
  • London, UK, 19 April 2023 – 30 Technology, the world leader in clinical nitric oxide generation technology for health care, today announced that it has completed the sale of its antimicrobial nitric oxide platform in certain applications to Convatec Group Plc (LSE: CTEC).
  • As part of the transaction, a small team from 30 Technology will transfer across to Convatec.
  • Syd Hanna, Group Executive Director of 30 Technology commented: “This transaction validates 30 Technology’s transformational approach to unlock the potential of nitric oxide to treat a range of infections with a durable and safe treatment.
  • Stifel acted as financial advisor and Goodwin Procter provided legal counsel to 30 Technology.

Nicox Provides First Quarter 2023 Financial and Business Highlights

Retrieved on: 
水曜日, 4月 19, 2023
Mont Blanc, NCX, IOP, ARVO, COVID-19, Nitric oxide, American Glaucoma Society, WGC, Intraocular pressure, Bausch & Lomb, Glaucoma, Congress, Ocular hypertension, Euronext Paris, Publication, Patient, Allergic conjunctivitis, Lifting, Communication, Marshal of France, Association for Research in Vision and Ophthalmology, Research, Annual report, COX, AGS, Pharmaceutical industry, Ophthalmology

Cash position of €21.4 million as of March 31, 2023

Key Points: 
  • Cash position of €21.4 million as of March 31, 2023
    Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided financial and business highlights for the first quarter 2023 for Nicox SA and its subsidiaries (the “Nicox Group”).
  • As of March 31, 2023, the Nicox Group had cash and cash equivalents of €21.4 million as compared with €27.7 million as of December 31, 2022.
  • The payment of this debt would only occur if the put option was exercised, subject to the conditions set out in footnote 2 below.
  • VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% U.S. prescriptions3 increased by 23% in the first quarter of 2023 compared to the same period in 2022.

What Does Ginseng Have to Do With Libido?

Retrieved on: 
水曜日, 4月 5, 2023
Tribulus terrestris, Blood, Premature ejaculation, Tissue, Male, Nitric oxide, System, Depression, Oxidative stress, ED, Libido, Dietary supplement

Premature ejaculation, excessive alcohol consumption, and depression (many of which are lumped under the umbrella term “erectile dysfunction” or ED) can all exacerbate poor libido.

Key Points: 
  • Premature ejaculation, excessive alcohol consumption, and depression (many of which are lumped under the umbrella term “erectile dysfunction” or ED) can all exacerbate poor libido.
  • The creator of the natural libido-enhancing supplement Male Plus has worked as both a male beautician and fitness coach.
  • Beyond that, Ginseng is present in the Male Plus formula to boost energy, calm the body, and destress the mind.
  • “While Tribulus Terrestris and Maca Root are there to help with function, Ginseng sets the stage,” explains Torfs, “It’s an important step.

Healthy Extracts Reports Record Fiscal Year 2022 Financial Results

Retrieved on: 
金曜日, 3月 31, 2023
Online, Exercise, Heart, Blood, Ultimate Brain, Sports medicine, Migraine, 8-K, BRAIN, Nitric oxide, OTCQB, Medicine, VO2 max, Marketing, Nature, Acquisition, Publication, Brain, Patient, Hyperion, Growth, VO2, UBN, Sport, Vitamin Cottage Natural Grocers, Brain activity and meditation, Whitney, Biomedical Advanced Research and Development Authority, Pharmaceutical industry, Film industry, Life insurance, Dietary supplement, Retail, Amazon

LAS VEGAS, March 31, 2023 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading developer and distributor of plant-based nutraceutical products for heart and brain health, reported results for the year ended December 31, 2022.

Key Points: 
  • LAS VEGAS, March 31, 2023 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading developer and distributor of plant-based nutraceutical products for heart and brain health, reported results for the year ended December 31, 2022.
  • Normalizing for certain inventory utilization, gross margin was 65.2% in 2022 and 66.8% in 2021.
  • Healthy Extracts top brand influencer and renowned fitness expert, Whitney Johns, launched her new line of natural health products on whitneyjohns.com and the Whitney Johns Nutrition Amazon Store .
  • “Our record top-line for 2022 was driven by growing consumer demand for our expanded product offerings which were delivered through our broadening sales channels,” commented Healthy Extracts president, Duke Pitts.

NCCAOM has elected Dr. Janet Zand as the new Chair of its Board of Commissioners

Retrieved on: 
月曜日, 4月 10, 2023
Biological functions of nitric oxide, Acupuncture, Partnership, Chairperson, National Certification Commission for Acupuncture and Oriental Medicine, Herbal medicine, Traditional Chinese medicine, Private practice, COVID, Commissioner, Child, Organization, Nitric oxide, NO, Patient, Fremantle Football Hall of Legends, Physician, Nursing, Hall, Montgomery County Board of Commissioners, NCCAOM, Mental health, Nation, Parent, Substance abuse

WASHINGTON, April 10, 2023 /PRNewswire-PRWeb/ -- Dr. Zand has over thirty years of private practice experience in natural medicine including: acupuncture, herbal medicine, functional medicine and nutrition. With the NCCAOM governed by its Chief Executive Officer and 9 Commissioners, the Board Chair has a significant impact on furthering the organization's mission.

Key Points: 
  • The National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM)® has elected Dr. Janet Zand as the new Chair of its Board of Commissioners.
  • As Chair, Dr. Zand will continue to be an advocate of qualified acupuncturists through NCCAOM National Board Certification.
  • "The NCCAOM is pleased to have Dr. Zand begin her service as the Chair of the NCCAOM Board of Commissioners.
  • We are happy to announce that Dr. Majd will continue to serve on the NCCAOM Board of Commissioners as Immediate Past Chair.

AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244

Retrieved on: 
木曜日, 4月 6, 2023
AOB, Nitrosomonas eutropha, Rosacea, European Patent Office, Nitric oxide, Skin, Psoriasis, Inflammation, EPO, Composition, Vasodilation, European Patent Organisation, SAE, Patent, Patient, Ammonia, EP, European Patent Convention, AOBiome, Therapy, Pharmaceutical industry, Dermatitis, Acne

CAMBRIDGE, Mass., April 6, 2023 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage biotech company focusing on inflammatory conditions, today announced that the European Patent Office (EPO) has issued a composition of matter patent, EP Patent No. 3132021, with claims focused on its proprietary strain of beneficial AOB, in the class of Nitrosomonas eutropha. The base patent term extends until April 15, 2035, excluding patent term extensions or coverage in additional related patent filings.

Key Points: 
  • -  AOBiome's clinical candidate B244 has demonstrated clinical efficacy on multiple therapeutic indications including: Mild-to-Moderate Atopic Dermatitis and associated Moderate-to-Severe Pruritus, and mild-to-moderate Acne Vulgaris
    CAMBRIDGE, Mass., April 6, 2023 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage biotech company focusing on inflammatory conditions, today announced that the European Patent Office (EPO) has issued a composition of matter patent, EP Patent No.
  • The base patent term extends until April 15, 2035, excluding patent term extensions or coverage in additional related patent filings.
  • This patent follows on other related issued composition of matter patents in Japan, Canada, India and Australia.
  • "Getting a composition of matter patent speaks to the unique aspects of this proprietary strain of AOB which has shown superior growth, stability and metabolic activity when compared to other strains.

Novan Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
木曜日, 3月 30, 2023
Rosacea, EPI, Satō, Drug development, SG, File, Marketing, Novin, NDA, Health, Nitric oxide, Research, Research and development, Development, Acquisition, Molluscum contagiosum, PDUFA, Webcast, SB206, Growth, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Conference, Food, Pharmaceutical industry, Cryptocurrency, Video game, Dermatology

DURHAM, N.C., March 30, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the full year ended December 31, 2022 and provided a corporate update. The Company will host a conference call and webcast, today, March 30, 2023, at 8:30 a.m. ET (details below).

Key Points: 
  • ET –
    DURHAM, N.C., March 30, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the full year ended December 31, 2022 and provided a corporate update.
  • As of December 31, 2022, Novan had a total cash and cash equivalents balance of $12.3 million.
  • Novan reported total revenue of $23.7 million and $3.0 million for the year ended December 31, 2022 and 2021, respectively.
  • 61% growth in 2022 compared to 2021;
    68% growth in fourth quarter 2022 compared to fourth quarter 2021; and
    13% decrease in fourth quarter 2022 compared to third quarter 2022.

Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer

Retrieved on: 
木曜日, 3月 23, 2023
Hospice and palliative medicine, Employment, Portola Pharmaceuticals, UNO, Biotechnology, Harvard Medical School, Nitric oxide, Urinary tract infection, Doctor of Philosophy, Sale, Georgetown University, Tulane University, NO, Acquisition, Alexion Pharmaceuticals, Patient, Atmosphere of Earth, Hospital, FDA, Massachusetts General Hospital, Pulmonary hypertension, Therapy, Inducement, RSU, Pharmaceutical industry

Dr. Andrew Colin, the Company’s incumbent Chief Medical Officer, has transitioned to the role of Senior Medical Director Global Clinical Leadership and will remain an integral part of the Beyond Air team.

Key Points: 
  • Dr. Andrew Colin, the Company’s incumbent Chief Medical Officer, has transitioned to the role of Senior Medical Director Global Clinical Leadership and will remain an integral part of the Beyond Air team.
  • Prior to industry, Dr. Myers was a cardiothoracic surgeon for nine years, most recently at Massachusetts General Hospital.
  • “We are excited to appoint Dr. Myers as our Chief Medical Officer.
  • Dr. Myers also served as the Chief Medical Officer for Portola Pharmaceuticals where he was instrumental in the acquisition by Alexion Pharmaceuticals, and Vice President, Medical and Regulatory Affairs, at SteadyMed Therapeutics.

Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congress

Retrieved on: 
火曜日, 3月 21, 2023
Mont Blanc, NCX, Latanoprost, IOP, Legacy Devers Eye Institute, Denali, State University of New York Upstate Medical University, OR, Nitric oxide, TM, WGC, Intraocular pressure, Glaucoma, Congress, Euronext Paris, Ocular hypertension, NO, MD, Patient, Trabecular meshwork, COX, Safety, Pharmaceutical industry, Ophthalmology

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress (WGC) which will be held from June 28 to July 1st, 2023 in Rome, Italy.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced presentations of additional NCX 470 data at the 10th World Glaucoma Congress (WGC) which will be held from June 28 to July 1st, 2023 in Rome, Italy.
  • Poster Title: Effects of NCX 470, a Nitric Oxide (NO)-Donating Bimatoprost, in in vitro 3D-Human Trabecular Meshwork (TM) / Schlemm's Canal (SC) Co-Culture Tissue Model
    Presenter: Robert Fechtner, MD, Chair of the Department of Ophthalmology at SUNY Upstate Medical University in Syracuse, NY, U.S.
    Presenter: Steven Mansberger, MD, Vice-Chair, Director of Glaucoma Services and Ophthalmic Clinical Trials for the Devers Eye Institute in Portland, OR, U.S.
    NCX 470 is a novel nitric oxide (NO)-donating bimatoprost currently in Phase 3 clinical development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
  • The first Phase 3 trial Mont Blanc, a randomized, double-masked, multi-center, parallel group trial conducted in the U.S., comparing NCX 470 (0.1%) to latanoprost (0.005%) was completed in October 2022.
  • The second Phase 3 trial, Denali, similarly designed to the Mont Blanc trial, and which includes a long-term safety extension, is ongoing.